SHORT MINI-FUTURE - GENMAB | Market Closed - Deutsche Boerse AG 01:50:40 2024-05-31 pm EDT | ||
| 20.77 EUR | -0.38% |
|
| 1 month | +0.19% | ||
| 3 months | -1.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 20.77 | -0.38% |
| 24-05-30 | 20.85 | -1.28% |
| 24-05-29 | 21.12 | +0.76% |
| 24-05-28 | 20.96 | +2.49% |
| 24-05-27 | 20.45 | -1.02% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 01:50 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VQ9JYJ |
| ISIN | DE000VQ9JYJ7 |
| Date issued | 2021-07-13 |
| Strike | 3,495 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 13.93 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.21 € |
|---|---|
| Lowest since issue | 2.63 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,937
DKK
Average target price
2,466
DKK
Spread / Average Target
+27.30%
- Stock Market
- Certificates
- Certificat
